Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle View 
February 19, 2019Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management
November 8, 2018Pernix® Therapeutics Reports Third Quarter 2018 Financial Results
November 2, 2018Pernix Therapeutics to Report Third Quarter 2018 Financial Results on Thursday, November 8
September 12, 2018Pernix Therapeutics Holdings, Inc.’s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek®
August 27, 2018Pernix Therapeutics Announces Ruling in Patent Litigation Concerning Zohydro® ER with BeadTek®
August 9, 2018Pernix Therapeutics Reports Second Quarter 2018 Financial Results
August 1, 2018Pernix Therapeutics Announces a Series of Transactions to Strengthen Its Balance Sheet and Improve Financial Flexibility
July 31, 2018Pernix Therapeutics to Report Second Quarter 2018 Financial Results on Thursday, August 9
July 30, 2018Pernix Therapeutics Announces Successful Closing of Transaction Regarding Worldwide Rights to Contrave® for Weight Loss
June 22, 2018Pernix Therapeutics Announces Result of Bid Process for Acquisition of Worldwide Rights to Contrave® for Weight Loss
May 10, 2018Pernix Therapeutics Reports First Quarter 2018 Financial Results
May 1, 2018Pernix Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 10
April 23, 2018Pernix Therapeutics Announces Participation in Lead Bid for Acquisition of Worldwide Rights to Contrave® for Weight Loss
March 27, 2018Pernix Therapeutics Announces Return to Market of Zohydro® ER with BeadTek® 20 mg
March 8, 2018Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
February 22, 2018Pernix Therapeutics to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 8